Autopsy report · NCT00429403

Goserelin Acetate Study for Ovarian Function in Patients With Primary Breast Cancer

“Study stopped due to low accrual.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months after it had already started.
• Ran for about 3 years 11 months before it stopped.
• 1 participant enrolled.
• Results were posted on the registry 1 year after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

M.D. Anderson Cancer Center

Sponsor type

University, hospital or other

Conditions

Breast Cancer

Interventions

Goserelin

Participants

1

Sites

2

Countries

Japan, United States

Trials that died the same way

• Obstruction of Malignancy: Percutaneous Renal vs Endoscopic Stent
  “Study stopped due to lack of accrual” (94% match in meaning)
• Evaluation of 3TC or FTC Mono-therapy Compared to Continuing HAART as a Bridging Strategy
  “Study was halted for lack of accrual” (91% match in meaning)
• Sorafenib-induced Hand- Foot Skin Reaction Treatment
  “Study was halted due to poor subject accrual.” (90% match in meaning)
• Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence
  “Study discontinued due to low accrual.” (90% match in meaning)
• Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease
  “Study terminated due to low accrual.” (89% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.